The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Surrogate markers of intestinal dysfunction associated with survival in advanced cancers
Open accessAbstract
Deviations in the diversity and composition of the gut microbiota are called “gut dysbiosis”. They have been linked to various chronic diseases including cancers and resistance to immunotherapy. Stool shotgun based-metagenomics informs on the ecological composition of the gut microbiota and the prevalence of homeostatic bacteria such as Akkermansia muciniphila (Akk), while determination of the serum addressin MAdCAM-1 instructs on endothelial gut barrier dysfunction. Here we examined patient survival during chemo-immuno-therapy in 955 cancer patients across four independent cohorts of non-small cell lung (NSCLC), genitourinary (GU) and colorectal (CRC) cancers, according to hallmarks of gut dysbiosis. We show that Akk prevalence represents a stable and favorable phenotype in NSCLC and CRC cancer patients. Over-dominance of Akk above the healthy threshold was observed in dismal prognosis in NSCLC and GU and mirrored an immunosuppressive gut ecosystem and excessive intestinal epithelial exfoliation in NSCLC. In CRC, the combination of a lack of Akk and low sMAdCAM-1 levels identified a subset comprising 28% of patients with reduced survival, independent of the immunoscore. We conclude that gut dysbiosis hallmarks deserve integration within the diagnosis toolbox in oncological practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although not yet used clinically, stool miRNA panels are a novel dimension of the “exfoliome” of the gut epithelium that could furnish indirect readouts of microbiome status in disease.24,132”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [24]
Experimental — accuracy not yet measuredIn the citing paper
“Indeed, this trichotomic observation indicates a more complicated, non-linear relationship with anti-tumor immunity.24”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [24]
In the citing paper
“Our lab recently reported that low baseline sMAdCAM-1 levels are strongly associated with gut dysbiosis in cancer patients.4,24”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [24]
In the citing paper
“Notably, this “abnormal” relative abundance is accompanied by an increased “exfoliome” (exfoliated host cells and DNA in the stool) and relative dominance of the Enterocloster genus (Birebent et al., 2025).”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Birebent et al., 2025
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671 · cited 4×
“10 In particular, Akkermansia muciniphila 5,17 Lachnospiraceae (including Roseburia spp., Coprococcus spp., Dorea spp . among others), and Oscillospiraceae family members (such as Faecalibacterium prausnitzii , R. bromii, R. bicirculans ) were associated with clinical benefit to ICI, while oral…”
InfluentialSelf-citationGut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Self-citationCross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity
Everard, A., Belzer, C., Geurts, L., Ouwerkerk, J. P., Druart, C., Bindels, L. B., Guiot, Y., Derrien, M., Muccioli, G. G., Delzenne, N. M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219451110 · Cited by 4,511 · cited 1×
“41,45 50 A proof-of-concept study with 40 patients, showed that pasteurized, but not alive, MucT (10 10 cells per day for 3 months) markedly improved insulin sensitivity and cholesterol levels, altered metabolic profiles, and promoted lipid beta-oxidation.”
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107 · cited 1×
“5,7,19 To minimize these confounding factors, we focused on advanced non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and urothelial cancer (UC) which share GOMS, 5,17,18 in particular the immunogenic Akkermansia muciniphila ( Akk) and two species interacting groups (SIG) of bacteria…”
Depommier, C., Everard, A., Druart, C., Plovier, H., Van Hul, M., Vieira-Silva, S., Falony, G., Raes, J., Maiter, D., Delzenne, N. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0495-2 · Cited by 2,357 · cited 1×
“44,51 This pioneering and successful trial using this food supplement in metabolic disorders paves the way to the development of live biotherapeutics as potential drugs to be applied in the subset of cancer patients lacking endogenous A. muciniphila .”
Plovier, H., Everard, A., Druart, C., Depommier, C., Van Hul, M., Geurts, L., Chilloux, J., Ottman, N., Duparc, T., Lichtenstein, L., et al. (2017) · Nature Medicine · doi:10.1038/nm.4236 · Cited by 2,204
Gut microbiota dysbiosis contributes to the development of hypertension
Li, J., Zhao, F., Wang, Y., Chen, J., Tao, J., Tian, G., Wu, S., Liu, W., Cui, Q., Geng, B., et al. (2017) · Microbiome · doi:10.1186/s40168-016-0222-x · Cited by 1,685 · cited 1×
“43 Cani’s group explored these connections in rodents and in T2D/obese patients in Microbes4U© study.”
Blanco-Míguez, A., Beghini, F., Cumbo, F., McIver, L. J., Thompson, K. N., Zolfo, M., Manghi, P., Dubois, L., Huang, K. D., Thomas, A. M., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01688-w · Cited by 1,442
Self-citationYachida, S., Mizutani, S., Shiroma, H., Shiba, S., Nakajima, T., Sakamoto, T., Watanabe, H., Masuda, K., Nishimoto, Y., Kubo, M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0458-7 · Cited by 1,429 · cited 1×
“This may be due to distinct microbiota and biofilms associated with the colon tumorigenesis, 53 and/or to a relative loss of health-associated bacteria such as Christensenellaceae, Oscillospiraceae, Lachnospiraceae family members.”
Thomas, A. M., Manghi, P., Asnicar, F., Pasolli, E., Armanini, F., Zolfo, M., Beghini, F., Manara, S., Karcher, N., Pozzi, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0405-7 · Cited by 1,030 · cited 1×
“54 The shedding of MAdCAM-1, first described 20 years ago, occurs in the gut lymphoid tissues but also in the liver (in humans but not in mice).”
Self-citation
Research works printed but not linked: 1
- 10.1158/2159-8290.CD-21-0999 · DOI · Paper page
Cited by
Duttagupta, S., Messaoudene, M., Hunter, S., Desîlets, A., Jamal, R., Mihalcioiu, C. L. D., Belkaïd, W., Marcoux, N., Fidelle, M., Suissa, D., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04186-5 · Cited by 122
“Among R patients, a concomitant relative depletion of deleterious bacteria 14,30,31 , including E. lavalensis , Clostridium scindens and C. innocuum , was observed after FMT compared to baseline (Fig.”
InfluentialSelf-citationPorcari, S., CICCARESE, C., Heidrich, V., Rondinella, D., Quaranta, G., Severino, A., Arduini, D., Buti, S., Fornarini, G., Primi, F., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04189-2 · Cited by 67
“Notably, an overabundance of A. muciniphila was previously associated with resistance to ICIs and was highlighted as an indirect sign of dysbiosis (as observed in patients with a history of antibiotic exposure) 24,27 .”
InfluentialSelf-citationChen, C., Su, Q., Zi, M., Hua, X., & Zhang, Z. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00818-3 · Cited by 51
“Clinically, its depletion is associated with gut dysbiosis and reduced survival in CRC patients, underscoring its potential as both a therapeutic target and prognostic biomarker 93 .”
Gut dysbiosis in oncology: a risk factor for immunoresistance
(2026) · doi:10.1038/s41422-025-01212-6 · Cited by 24
“24 In this review, we examine the evolving conceptual frameworks for de fi ning and measuring dysbiosis in the context of ICI therapy.”
InfluentialSelf-citationMicrobiota-centered interventions to boost immune checkpoint blockade therapies
Almonte, A. A., Thomas, S., & Zitvogel, L. (2025) · Journal of Experimental Medicine · doi:10.1084/jem.20250378 · Cited by 19
Self-citation
Metadata
- Authors
- Birebent, R., Drubay, D., Alves Costa Silva, C., Marmorino, F., Vitali, G., Piccinno, G., Hurtado, Y., Bonato, A., Belluomini, L., Messaoudene, M., Routy, B., Fidelle, M., Zalcman, G., Mazieres, J., Audigier-Valette, C., Moro-Sibilot, D., Goldwasser, F., Scherpereel, A., Pegliasco, H., Ghiringhelli, F., Reni, A., Barlesi, F., Albiges, L., Planchard, D., Martinez, S., Besse, B., Segata, N., Cremolini, C., Zitvogel, L., Iebba, V., & Derosa, L.
- Affiliations
- Inserm (FR)
- Université Paris-Saclay (FR)
- Gustave Roussy Cancer Campus, ClinicObiome
- University of Pisa (IT)
- University of Trento (IT)
- University of Verona (IT)
- Centre Hospitalier de l’Université de Montréal (CA)
- Bichat-Claude Bernard Hospital, AP-HP, Université Paris Cité
- Centre Hospitalier Universitaire de Toulouse
- Centre Hospitalier Intercommunal Toulon-La Seyne-sur-Mer (FR)
- Centre Hospitalier Universitaire
- Université Paris Cité (FR)
- European Hospital (IT)
- Centre Hospitalier Intercommunal Aix-Pertuis (FR)
- Institut Gustave Roussy (FR)
- Corresponding author
- Derosa, Lisa
- ORCID
- Birebent, Roxanne
- Drubay, Damien
- Marmorino, Federica
- Piccinno, Gianmarco
- Bonato, Adele
- Belluomini, Lorenzo
- Messaoudene, Meriem
- Routy, Bertrand
- Fidelle, Marine
- Audigier-Valette, Clarisse
- Goldwasser, François
- Scherpereel, Arnaud
- Ghiringhelli, François
- Reni, Anna
- Albiges, Laurence
- Planchard, David
- Besse, Benjamin
- Segata, Nicola
- Cremolini, Chiara
- Zitvogel, Laurence
- Iebba, Valerio
- Derosa, Lisa
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2025-04-06
- Volume
- 14
- Issue
- 1
- Pages
- 2484880-2484880
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- PMC
- PMC11980478
- OpenAlex
- W4409204557
- Cited by
- 21
- References
- 58
- Citations by year
- 2026: 15 · 2025: 6
- FWCI
- 6.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- OncoImmunology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by-nc)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Iris (University of Trento) (submittedVersion, cc-by-nc)
- Funders
- European Research Council
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- gut dysbiosis, Akkermansia muciniphila, MAdCAM-1, intestinal barrier dysfunction, cancer survival, non-small cell lung cancer, colorectal cancer, genitourinary cancer, immune score, immunosuppression, prognostic factors, gut microbiota
- MeSH terms
- Gastrointestinal Microbiome, Akkermansia, Aged, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Prognosis, Urogenital Neoplasms, Colorectal Neoplasms, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Surrogate markers of intestinal dysfunction associated with survival in advanced cancers. https://app.cochat.ai/papers/10.1080/2162402x.2025.2484880
- The paper
- Birebent, R., Drubay, D., Alves Costa Silva, C., Marmorino, F., Vitali, G., Piccinno, G., Hurtado, Y., Bonato, A., Belluomini, L., Messaoudene, M., Routy, B., Fidelle, M., Zalcman, G., Mazieres, J., Audigier-Valette, C., Moro-Sibilot, D., Goldwasser, F., Scherpereel, A., Pegliasco, H., . . . Derosa, L. (2025). Surrogate markers of intestinal dysfunction associated with survival in advanced cancers. OncoImmunology. https://doi.org/10.1080/2162402x.2025.2484880
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.